On Wednesday, Following U.S. Stocks were among the “Top Losers”: Zogenix, (NASDAQ:ZGNX), Walter Energy, (NYSE:WLT),Blount International, (NYSE:BLT), Opexa Therapeutics, (NASDAQ:OPXA)

• Zogenix, (NASDAQ:ZGNX), with shares dwindled -26.95%, closed at $1.22.

• Walter Energy, (NYSE:WLT), with shares plunged -26.88%, settled at $0.57, hitting new 52-week low of $0.53.

• Blount International, (NYSE:BLT), with shares dipped -19.54%, and closed at $13.30.

• Opexa Therapeutics, Inc. (NASDAQ:OPXA), dropped -18.29%, and closed at $0.67, hitting new 52-week low of $0.65.

Latest NEWS regarding these Stocks are depicted underneath:

Zogenix, Inc. (NASDAQ:ZGNX)

Zogenix, Inc. (ZGNX), a pharmaceutical corporation developing and commercializing products for the treatment of central nervous system (CNS) disorders, declared that it has reached a definitive contract to sell its Zohydro(R) ER (hydrocodone bitartrate) business to Pernix Therapeutics (PTX) for $100 million plus regulatory and sales milestones up to $283.5 million. Both companies plan to transition the Zogenix sales team and other select employees to Pernix.

This transaction enables Zogenix to plannedally shift focus to its late-stage CNS clinical pipeline highlighted by two promising product candidates:

• ZX008, which has orphan drug designation in the US and EU for the treatment of Dravet syndrome and is predictable to enter Phase 3 development this year, and;
• Relday, a unique long-acting injectable formulation of risperidone for the maintenance treatment of schizophrenia that is predictable to be ready for Phase 3 studies in the first half of 2016.

The sale of Zohydro ER to Pernix significantly reduces operating expenses, eliminates all R&D expenses related to ongoing abuse-deterrent formulations, and further enhances the Corporation’s financial strength with non-dilutive capital.

Roger Hawley, chief executive officer of Zogenix said, “The submission and recent approval of the supplemental New Drug Application (sNDA) for Zohydro(R) ER with BeadTek(TM) was an important catalyst for increasing planned interest in the brand. We are very happy to have selected Pernix for this transaction as we believe they are well positioned to continue raising awareness of the important clinical benefits of Zohydro ER for patients suffering with severe chronic pain who are in need of around-the-clock opioid therapy. As a further benefit to those involved with Zohydro ER, upon closing both companies plan to transition the Zogenix sales team and other select commercial and medical affairs employees to Pernix. This will assist ensure uninterrupted customer support, a smooth transition and continued growth of the product. We thank our entire commercial and medical organizations for their achievements during the product’s first year on the market and look forward to continued efforts in the coming months by our sales team in driving adoption of Zohydro ER in the pain community.”

Zogenix, Inc. (ZGNX) is a pharmaceutical corporation committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and CNS disorders who need innovative treatment alternatives to assist them return to normal daily functioning.

Walter Energy, Inc. (NYSE:WLT)

Formerly on March 5, Walter Energy, Inc. (WLT), declared that the Corporation has been notified by the New York Stock Exchange that its ordinary stock does not presently satisfy one of the NYSE’s continued listing standards. The NYSE requires that the average closing price per share of a listed corporation’s ordinary stock be at least $1.00 over a successive 30 trading-day period. As of March 3, 2015, the average closing price per share of the Corporation’s ordinary stock over the preceding 30 trading-day period was $0.99.

Formerly on February 17, a leading, publicly traded “pure-play” producer of metallurgical (“met”) coal for the global steel industry, declared results for the quarter and year ended December 31, 2014.

Full-Year 2014 Merged Financial Results:

Walter Energy stated a net loss in 2014 of $470.6 million, or $7.10 per diluted share, contrast with a net loss of $359.0 million, or $5.74 per diluted share, in 2013. Comprised of in the Corporation’s financial results are non-cash revenue tax charges and credits, restructuring and asset impairment costs, transportation take-or-pay costs, gains on the early extinguishment of debt and other items. Not including these items, the adjusted net loss for 2014 was $449.8 million, or $6.79 per diluted share. The adjusted net loss for 2013 totaled $237.3 million, or $3.79 per diluted share.

Walter Energy is a leading, publicly traded “pure-play” metallurgical coal producer for the global steel industry with planned access to steel producers in Europe, Asia and South America. The Corporation also produces thermal coal, anthracite, metallurgical coke and coal bed methane gas. Walter Energy employs about 2,700 employees, with operations in the United States, Canada and United Kingdom.

Blount International Inc. (NYSE:BLT)

Blount International Inc. (BLT), declared results for the fourth quarter and full year ended December 31, 2014.

Results for the Quarter and Full Year Ended December 31, 2014:

Sales in the fourth quarter were $232.2 million, an raise of $15.3 million or seven percent contrast to the fourth quarter of 2013. Operating loss for the fourth quarter of 2014 was $2.5 million contrast to an operating loss of $16.5 million in the same quarter last year. Adjusted EBITDA in the fourth quarter was $30.5 million, an raise of $6.0 million or 24 percent contrast to the fourth quarter of 2013. Fourth quarter net loss was $2.4 million, or $0.05 per diluted share, contrast to net loss of $21.5 million, or $0.43 per diluted share, in the fourth quarter of 2013.

Sales for the full year were $944.8 million, an raise of $44.2 million or five percent contrast to full year 2013. Operating revenue for 2014 was $64.2 million contrast to operating revenue of $37.5 million for full year 2013. Adjusted EBITDA for full year 2014 was $138.0 million, an raise of $14.5 million or 12 percent contrast to full year 2013. The full year 2014 net revenue was $36.6 million, or $0.73 per diluted share, contrast to net revenue of $4.8 million, or $0.10 per diluted share, for full year 2013.

“We operated well in 2014, and our results reflect our performance and stronger demand in our core business contrast to the previous year,” stated Josh Collins, Blount’s Chairman and CEO. “Our continued focus on Operational Excellence and our targeted cost reductions positively influenced our results for the quarter and the full year.”

Collins continued, “Looking ahead to 2015, we remain focused on operating well and executing on our planned plan. While the underlying fundamentals of our business are sound, we are experiencing noteworthy headwinds from foreign currency markets related to the strength of the U.S. Dollar.”

Blount International, Inc., together with its auxiliaries, designs, manufactures, and markets equipment, replacement and component parts, and accessories to forestry, lawn and garden, farm, ranch, agriculture, and construction sectors primarily in the United States and Europe. It operates in two segments, the Forestry, Lawn, and Garden; and Farm, Ranch, and Agriculture.

Opexa Therapeutics, Inc. (NASDAQ:OPXA)

Opexa Therapeutics, Inc. (OPXA), a corporation developing personalized immunotherapies for autoimmune disorders, counting multiple sclerosis (MS) and neuromyelitis optica (NMO), provides shareholders a reminder of its rights offering and its calendar, as shareholders should ensure they own Opexa’s stock as of 4:00 PM ET on Tuesday, March 10, 2015 to be considered a shareholder of record on Friday, March 13, 2015.

Opexa Therapeutics, Inc., a biopharmaceutical corporation, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The corporation was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.